Ensartinib (generic name) is a targeted therapy drug primarily indicated for patients with ALK-positive non-small cell lung cancer (NSCLC). Its price is affected by factors such as specifications, regions, and medical insurance policies. In China, the price per box usually ranges from 720to 1,500 USD. The actual price shall prevail at medical institutions or licensed pharmacies. This drug is a prescription medication and must be used strictly in accordance with the doctor’s instructions.
Notes on Price
Specification Differences
The common specifications of Ensartinib are 100 mg per capsule × 28 capsules per box and 150 mg per capsule × 28 capsules per box. Prices may vary with different specifications.
Medical Insurance Policies
The drug may be included in the medical insurance reimbursement scope in some regions. Patients can consult the local medical insurance department about the specific reimbursement ratio with medical records.
Imported vs. Domestic Products
Currently, the Ensartinib marketed in China is a domestic original research drug. The price of imported similar drugs (e.g., other ALK inhibitors) may be higher (over 10,000 yuan per box).
Medication Precautions
Follow Doctor’s Instructions Strictly
The dosage should be adjusted based on the patient’s condition, body weight, and tolerance. Do not increase, decrease the dosage or discontinue the drug without authorization.
Adverse Reaction Monitoring
Side effects such as fatigue, skin rash, and abnormal liver function may occur. Regular reexaminations of blood routine, liver and kidney functions are required.
Medication Purchase Channels
The drug must be purchased with a prescription from hospitals or licensed pharmacies to avoid the risks of medication through unauthorized channels.
It is recommended that patients visit the oncology department or respiratory medicine department. Doctors will evaluate the patient’s condition before issuing a prescription and formulating an individualized treatment plan. During the treatment period, patients should maintain regular follow-up visits to facilitate timely adjustment of the medication plan.
